Next Article in Journal / Special Issue
Clinicopathological and Functional Evaluation Reveal NBS1 as a Predictor of Platinum Resistance in Epithelial Ovarian Cancers
Previous Article in Journal
Inflammatory Mediators and Pain in Endometriosis: A Systematic Review
Previous Article in Special Issue
Anti-HER2/neu Antibody Reduces Chemotherapy-Induced Ovarian Toxicity—From Bench to Bedside
Open AccessArticle

Role of BRCA Mutation and HE4 in Predicting Chemotherapy Response in Ovarian Cancer: A Retrospective Pilot Study

1
Department of Obstetrics and Gynecology, University ‘‘Campus Bio-Medico’’ of Rome, Via Alvaro del Portillo, 200-00128 Rome, Italy
2
Unit of Medical Statistics and Molecular Epidemiology, University Campus Bio-Medico of Rome, 00128 Rome, Italy
3
Department of Gynecology, Obstetrics and Urology, Policlinico Umberto I, “Sapienza” University of Rome, 00161 Rome, Italy
*
Author to whom correspondence should be addressed.
Biomedicines 2021, 9(1), 55; https://doi.org/10.3390/biomedicines9010055
Received: 9 November 2020 / Revised: 30 December 2020 / Accepted: 31 December 2020 / Published: 8 January 2021
Even though 80% of patients with High-Grade Serous Ovarian Cancer respond to standard first-line chemotherapy, a majority of them could relapse in the following five years due to a resistance to platinum. Human Epididymis protein 4 (HE4) is one of the most promising markers in predicting platinum therapy response. This pilot study aims to evaluate the potential role of HE4 value in predicting chemotherapy response in BRCA mutated patients and in BRCA wild-type (non-mutated) ones. We selected 69 patients, affected by High-Grade Serous Ovarian Cancer, and optimally debulked and submitted to standard chemotherapy protocols. HE4 was dosed during every chemotherapy course. Patients were classified as platinum-resistant and platinum-sensitive. According to BRCA mutation test, patients were further divided into BRCA wild-type (53 patients), and BRCA mutated (16 patients). 35 patients out of 69 (52%) were platinum-sensitive (recurrence > 12 months), while 33 patients (48%) were platinum-resistant (recurrence < 12 months). Thus, in the total population, HE4 performed as a marker of chemosensitivity with a sensibility of 79% and a specificity of 97%. In the BRCA WT group, 23 patients out of 53 (43%) were platinum-sensitive, while 30 patients out of 53 (57%) were platinum-resistant. In the BRCA WT group, HE4 performed as a predictive marker of chemosensitivity with a sensibility of 80% and a specificity of 100%. In the BRCA mutated group, 13 patients out of 16 (82%) were platinum-sensitive, while 3 patients (18%) were platinum-resistant. In the BRCA mutated group, HE4 performed as a predictive marker of chemosensitivity in all patients. The ability to detect platinum-resistant patients before tumor relapse probably could open new therapeutic scenarios. View Full-Text
Keywords: ovarian cancer; HE4; BRCA; chemotherapy response ovarian cancer; HE4; BRCA; chemotherapy response
Show Figures

Figure 1

MDPI and ACS Style

Plotti, F.; Terranova, C.; Guzzo, F.; De Cicco Nardone, C.; Luvero, D.; Bartolone, M.; Dionisi, C.; Benvenuto, D.; Fabris, S.; Ciccozzi, M.; Di Donato, V.; Panici, P.B.; Angioli, R. Role of BRCA Mutation and HE4 in Predicting Chemotherapy Response in Ovarian Cancer: A Retrospective Pilot Study. Biomedicines 2021, 9, 55. https://doi.org/10.3390/biomedicines9010055

AMA Style

Plotti F, Terranova C, Guzzo F, De Cicco Nardone C, Luvero D, Bartolone M, Dionisi C, Benvenuto D, Fabris S, Ciccozzi M, Di Donato V, Panici PB, Angioli R. Role of BRCA Mutation and HE4 in Predicting Chemotherapy Response in Ovarian Cancer: A Retrospective Pilot Study. Biomedicines. 2021; 9(1):55. https://doi.org/10.3390/biomedicines9010055

Chicago/Turabian Style

Plotti, Francesco; Terranova, Corrado; Guzzo, Federica; De Cicco Nardone, Carlo; Luvero, Daniela; Bartolone, Martina; Dionisi, Camilla; Benvenuto, Domenico; Fabris, Silvia; Ciccozzi, Massimo; Di Donato, Violante; Panici, Pierluigi B.; Angioli, Roberto. 2021. "Role of BRCA Mutation and HE4 in Predicting Chemotherapy Response in Ovarian Cancer: A Retrospective Pilot Study" Biomedicines 9, no. 1: 55. https://doi.org/10.3390/biomedicines9010055

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop